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Novelty statement 
 What is already known? Diagnosis of non-diabetic hyperglycaemia is a key component of 
diabetes prevention programmes and clinical practice.  Non-diabetic hyperglycaemia 
diagnosis with a single test often changes to normality when re-tested.  
 What has this study found? Classification based on both HbA1c and fasting plasma 
glucose independently predicted discordant diagnosis of non-diabetic hyperglycaemia and 
type 2 diabetes.  
 What are the clinical implications of the study? Diagnosis of non-diabetic hyperglycaemia 
and type 2 diabetes should be based on two HbA1c measurements.    
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Abstract 
Aim: To investigate factors influencing diagnostic discordance for non-diabetic 
hyperglycaemia and type 2 diabetes. 
Methods: 10,000 adults at increased risk of diabetes were screened with HbA1c and fasting 
plasma glucose (FPG). The 2,208 with initial HbA1c >42 mmol/mol (>6.0%) or FPG > 6.1 
mmol/L were retested after a median 40 days. We compared the first and second HbA1c 
results, and consequent diagnoses of non-diabetic hyperglycaemia and type 2 diabetes, and 
investigated predictors of discordant diagnoses.  
Results: Of 1,463 participants with non-diabetic hyperglycaemia and 394 with type 2 diabetes 
on first testing, on repeated testing 28.4% and 21.1%, respectively,  had discordant diagnoses. 
Initial diagnosis of non-diabetic hyperglycaemia and/or impaired fasting glucose according to 
both HbA1c and FPG criteria, or to FPG only, made reclassification as type 2 diabetes more 
likely than initial classification according to HbA1c alone. Initial diagnosis of type 2 diabetes 
according to both HbA1c and FPG criteria made reclassification much less likely than initial 
classification according to HbA1c alone. Age, and anthropometric and biological 
measurements independently but inconsistently predicted discordant diagnoses and changes 
in HbA1c.  
Conclusions: Diagnosis of non-diabetic hyperglycaemia or type 2 diabetes with a single 
measurement of HbA1c in a screening programme for entry to diabetes prevention trials is 
unreliable. Diagnosis of non-diabetic hyperglycaemia and type 2 diabetes should be confirmed 
by repeat testing. FPG results could help prioritise retesting. These findings do not apply to 
people classified as normal on a single test, who were not retested.  
Keywords: diagnosis, non-diabetic hyperglycaemia, reproducibility, type 2 diabetes  
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Introduction 
The prevalence of type 2 diabetes mellitus is increasing rapidly worldwide [1,2]. This has 
prompted population-wide national diabetes prevention programmes, usually based on 
identifying people at highest risk of Type 2 diabetes using plasma glucose or haemoglobin 
A1c (HbA1c; glycated haemoglobin) data, who are then offered a lifestyle intervention to 
reduce the risk of  progression to type 2 diabetes [3]. Randomised trials have shown that such 
interventions can be effective in preventing diabetes, but identification of the highest risk 
people can be problematic because of imperfect validity and reliability of diagnostic tests and 
because of recognised analytical and biological variation [4]. Changes in the diagnostic criteria 
for diabetes, from glucose based criteria (fasting plasma glucose (FPG) or oral glucose 
tolerance test) to measurement of haemoglobin A1c (HbA1c; glycated haemoglobin), has 
generated a large population with non-diabetic hyperglycaemia who are deemed to be at 
increased risk of type 2 diabetes  [5-7]. In England the National Health Service (NHS) launched 
a national diabetes prevention programme in 2015, in which people diagnosed with non-
diabetic hyperglycaemia are offered dietary and lifestyle counselling [5-6]. There are 
equivalent models in the United States   [7]. 
An important but neglected problem with diagnosis of non-diabetic hyperglycaemia is that 
people diagnosed with non-diabetic hyperglycaemia on the basis of a single test   may   have 
normal values if retested soon after. NHS policy is that asymptomatic adults must have paired 
HbA1c testing before diagnosis of type 2 diabetes [8], as recommended by the World Health 
Organisation and the American Diabetes Association [9,10]. However for non-diabetic 
hyperglycaemia only one test is required to be eligible for the diabetes prevention programme 
[11]. If incorrectly diagnosed as  having non-diabetic hyperglycaemia they may be 
unnecessarily labelled as being at high risk of diabetes, and exposed to costly and 
inconvenient preventive interventions.  Population based diabetes programmes need 
evidence about the repeatability of non-diabetic hyperglycaemia screening, to help decide 
whether and in whom screening tests should be repeated before starting lifestyle interventions 
and treatment.  
The present study is based on targeted screening data from the Norfolk Diabetes Prevention 
Study (NDPS, ISRCTN34805606) [12]. The study entailed testing over 12,000 adults with 
known risk factors for previously undiagnosed non-diabetic hyperglycaemia, impaired fasting 
glucose (IFG) and type 2 diabetes. Those whose HbA1c or FPG measurements indicated that 
they had non-diabetic hyperglycaemia, impaired fasting glucose (IFG) or type 2 diabetes were 
tested again for HbA1c and FPG a median of 40 days later. If their second test confirmed non-
diabetic hyperglycaemia, IFG or type 2 diabetes they were invited to participate in various 
trials. We report elsewhere on the results of screening, including the prevalence of non-
diabetic hyperglycaemia, IFG and type 2 diabetes, participant characteristics associated with 
these diagnostic classifications, and differences between initial and repeated diagnostic 
classifications, in the first 10,000 participants screened [13]. In the present analysis we focus 
on the anthropometric and biochemical factors associated with discordant non-diabetic 
hyperglycaemia or type 2 diabetes classification, and with discrepancies in HbA1c, on 
retesting. The purpose of this analysis is to investigate whether one can identify individuals 
who most need repeated testing, because they are most likely to have a change in diagnosis 
if retested.  
The objectives of the present study were i) to compare initial and second HbA1c values 
recorded in each individual, ii) to estimate the probabilities of concordant or discordant 
diagnoses of non-diabetic hyperglycaemia and type 2 diabetes, iii) to investigate how initial 
HbA1c and FPG values, alone and in combination, predicted change from non-diabetic 
hyperglycaemia to normal glycaemic classification or to type 2 diabetes, and iv) to investigate 
whether other participant characteristics, anthropometric measurements and biochemical 
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measurements independently predicted change in HbA1c and discordant classification of non-
diabetic hyperglycaemia and type 2 diabetes.   
PARTICIPANTS AND METHODS 
Design and population 
This was a cross sectional study based on data gathered from the NDPS [12]. NDPS evaluates 
the efficacy of dietary and lifestyle counselling interventions which aim to prevent progression 
of non-diabetic hyperglycaemia or IFG to type 2 diabetes, and to improve management of 
newly diagnosed type 2 diabetes. NDPS aimed to screen over 10,000 people at highest risk 
of non-diabetic hyperglycaemia, IFG or type 2 diabetes and to randomize approximately 1,600 
to several clinical trials. The size of the sample to be screened was calculated to enable 
differences in the primary outcomes to be estimated with 5% significance and 80% power [12].    
The NDPS population comprised adults with known risk factors for previously undiagnosed 
non-diabetic hyperglycaemia, IFG or type 2 diabetes in the East Anglia region of England. 
Participants were initially identified through general practice electronic medical records as 
being at high risk of non-diabetic hyperglycaemia, IFG or type 2 diabetes, as defined below, 
and tested by HbA1c and fasting plasma glucose (FPG). If they initially tested positive for non-
diabetic hyperglycaemia, IFG or type 2 diabetes, they were tested again to confirm their 
diagnosis. NDPS contacted 194 general practices in Norfolk, Suffolk, and North East Essex. 
By March 2016, 135 general practices participated, with a combined practice population of 1.8 
million. All individuals were contacted if their general practice electronic health records 
indicated no known diabetes and a) age ≥ 50 and body mass index (BMI) ≥ 30kg/m2; or b) age 
≥ 50 years and BMI ≥ 25kg/m2 and recorded first degree family history of type 2 diabetes, 
coronary artery disease, or gestational diabetes; or c) any previous record of IFG, impaired 
glucose tolerance (IGT) or FPG 6.1-7.0 mmol/L; or d) any record of HbA1c 42-48 mmol/mol 
(6.0-6.5%) and FPG 5.6-6.9 mmol/L. 141,973 people satisfying these criteria were contacted, 
and 12,778 (9%) registered for participation. The present study included all individuals who 
had non-diabetic hyperglycaemia, IFG or type 2 diabetes on initial HbA1c or FPG test, among 
the first 10,000 tested.   
Data collection 
Following an overnight fast, participants underwent venesection for FPG and HbA1c, and 
demographic, anthropometric and biochemical data were recorded. Follow-up tests for both 
HbA1c and FPG were conducted for all individuals whose initial HbA1c or FPG results 
indicated non-diabetic hyperglycaemia, IFG or type 2 diabetes. Repeated venesection for 
measurement of HbA1c and FPG was carried out a median of 40 (interquartile range 27-69) 
days after the first venesection.  For this study non-diabetic hyperglycaemia was defined as 
HbA1c 42 to 47 mmol/mol (6.0% to 6.4%), IFG was defined as FPG >6.1 or >5.6 to <7.0 
mmol/L (depending on classification criteria at the time of testing), and type 2 diabetes was 
defined as HbA1c >48 mmol/mol (>6.5%) or FPG >7.0 mmol/L [14-16]. We used the latter 
definition of non-diabetic hyperglycaemia, instead of the American Diabetes Association's 
definition of prediabetes (39-47 mmol/mol (5·7-6·4%) [17]), so as to conform to current 
practice in the English National Health Service (NHS) where the range 42-47 mmol/mol (6.0% 
to 6.4%) is used in national diabetes prevention policy guidance  [14], in the national vascular 
screening programme  [18], and in the NHS diabetes prevention programme [19], which 
determined the choice of this range in the original programme protocol [12]. We were unable 
to use the American Diabetes Association's definition of prediabetes [17] for the statistical 
analyses reported in this paper because participants with initial HbA1c 39-41 mmol/mol (5.7-
5.9%) were not retested unless they also had initial FPG>5.6 or >6.1 mmol/L.  
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Anthropometric measurements (weight, body mass index, body fat mass, visceral fat, and 
body fat percentage) were measured with a Tanita body fat composition analyser (TANITA – 
Hoogoorddreef, 1011 BE, Amsterdam, the Netherlands. Model BC-420 MA). HbA1c was 
measured using Affinity high performance liquid chromatography (Hb9210: Menarini 
Diagnostics Ltd., Wokingham, UK). FPG was measured by a hexokinase/G-6-PDH method on 
an automated platform (Architect c8000: Abbott Diagnostics, Maidenhead, UK).   
Statistical analysis 
The statistical analysis aimed to estimate the prevalences, and to identify predictors, of 
discordant or confirmed diagnosis of non-diabetic hyperglycaemia and type 2 diabetes and 
changes in HbA1c. Statistical analysis was performed with STATA version 15 (StataCorp, 
Texas) software.  A 5% significance level was used.   
Discordant non-diabetic hyperglycaemia was defined as diagnosis of non-diabetic 
hyperglycaemia on initial HbA1c test combined with diagnosis of normality or type 2 diabetes 
on the second HbA1c test. Discordant type 2 diabetes was defined as diagnosis of type 2 
diabetes on initial HbA1c test combined with diagnosis of normality or type 2 diabetes on the 
second HbA1c test.  
Summary statistics were computed as means and standard deviations, or counts and 
proportions. We tested whether participant characteristics, anthropomorphic measurements 
or biochemical measurements were associated with discordant diagnoses of non-diabetic 
hyperglycaemia or type 2 diabetes, first using chi square and t tests.   
We assessed the added value of FPG in predicting discordant diagnosis of non-diabetic 
hyperglycaemia and of type 2 diabetes, as follows. We cross-tabulated the initial classification 
of non-diabetic hyperglycaemia and/or IFG based on initial HbA1c and/or FPG (5.6-7.0 
mmol/L) results with classification of normality, non-diabetic hyperglycaemia or type 2 
diabetes based on second HbA1c results. We then tested the independent associations 
between these initial classifications and the three possible classifications based on second 
HbA1c results, using multinomial logistic regression. Non-diabetic hyperglycaemia was 
defined as the base outcome category. In this model we included baseline covariates that 
were associated with discordant non-diabetic hyperglycaemia at 10% significance level (Table 
1), and weeks from first to second HbA1c test. However, because body mass index and body 
fat mass were highly correlated with each other (Pearson R2=0.88) and because both are 
measures of adipositity, we excluded body fat mass from the models.  
We cross-tabulated the initial classification of type 2 diabetes, based on initial HbA1c and/or 
FPG results, with subsequent classification of normality, non-diabetic hyperglycaemia or type 
2 diabetes, based on second HbA1c results. Because very few participants changed from type 
2 diabetes to normality we pooled them with those who changed to non-diabetic 
hyperglycaemia to create a binary outcome indicating discordance. We constructed a logistic 
regression model with discordant classification of type 2 diabetes as outcome. Model 
covariates were initial HbA1c and/or FPG classification of type 2 diabetes, baseline variables 
associated with discordant type 2 diabetes at 10% significance level (Table 1), except for body 
fat mass, and weeks from first to second HbA1c test. 
We calculated the difference between the second and first HbA1c results, and tested 
whether this difference was independently associated with initial HbA1c, initial FPG or with 
other participant characteristics, biological or anthropomorphic measurements, using 
multiple linear regression models. Linear regression analyses were conducted separately for 
participants with initial diagnoses of non-diabetic hyperglycaemia or type 2 diabetes. All 
variables listed in Table 1 were initially included as potential explanatory variables, and then 
removed if they were not independently associated with change in HbA1c in either subgroup 
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at 10% significance level.  We retained the same covariates in the final models for both 
subgroups to enable comparison between the subgroups.  
Although various regression-based methods could be used to evaluate the incremental value 
of additional assays for diagnosis [20,21], they were unsuitable for our purpose of examining 
factors associated with discordant results of a single assay.  
All participants gave written informed consent to participate. Ethical review and approval was 
provided by the National Research Ethics Service (NRES), Essex 1 Research Ethics 
Committee (10/H0301/55; 13.1.2011). The study was carried out according to NRES 
permissions and with research governance approval from the sponsor organisation (Norfolk 
and Norwich University Hospital NHS Foundation Trust). 
RESULTS 
A total of 2208 participants whose initial HbA1c or FPG results indicated non-diabetic 
hyperglycaemia, IFG or type 2 diabetes were retested and comprised the sample described 
in the present study.  These participants were mostly white British nationals, with mean age 
65 years, mean BMI 31 Kg/m2, and 42% had a family history of type 2 diabetes (Table 1).  
Discordant classification of non-diabetic hyperglycaemia was more likely in participants with 
higher BMI, body fat mass, diastolic blood pressure, triglycerides and weeks between tests, 
and with lower age, initial HbA1c  and initial FPG (Table 1). Discordant classification of type 2 
diabetes was more likely in participants with lower BMI, waist circumference, body fat 
percentage, body fat mass, initial HbA1c, initial FPG, and weeks between tests (Table 1). 
Of 1463 with initial HbA1c values indicating non-diabetic hyperglycaemia, on repeated testing 
71.6% had non-diabetic hyperglycaemia confirmed, 21.3% had lower values indicating 
normality and 7.1% had values indicating type 2 diabetes. When classification of IFG or non-
diabetic hyperglycaemia based on initial FPG and HbA1c results were considered together 
(Table 2),  those with IFG and non-diabetic hyperglycaemia according to both assays were 
slightly more likely to be classified as having non-diabetic hyperglycaemia on repeated testing, 
compared to those with non-diabetic hyperglycaemia according to HbA1c only (74.4% vs. 
68.3%), but were much more likely than those initially with IFG according to FPG only (24.0%). 
Of 394 with initial HbA1c values indicating type 2 diabetes, 21.1% had lower values indicating 
NDH or normality later.  When classification of type 2 diabetes based on initial FPG and HbA1c 
results were considered together (Table 2),  those with type 2 diabetes according to both 
assays were more likely to be classified as having type 2 diabetes on repeated testing, 
compared to those with type 2 diabetes according to HbA1c only (90.7% vs. 71.7%), and much 
more likely than those initially with type 2 diabetes according to FPG only (11.5%). 
Multinomial logistic regression (Table 3) showed that, after adjustment for baseline covariates, 
those initially classified as having non-diabetic hyperglycaemia were not significantly moreor 
less likely to be reclassified as normal if they also initially had impaired fasting glucose than if 
they only had non-diabetic hyperglycaemia (relative risk ratio (RRR) 0.91 (95%CI 0.63-1.31)). 
They were more likely to be reclassified as having type 2 diabetes (RRR 1.62 (95%CI 0.94-
2.80)), but this association was not statistically significant (P=0.081). Without adjustment for 
covariates the respective RRRs were 0.58 (95%CI 0.45-0.76), P<0.001) and 5.0 (95%CI 3.8-
6.5), P<0.001), indicating that participants initially classified with both tests were less likely to 
be reclassified as normal and were more likely to be reclassified as type 2 diabetes on second 
HbA1c testing. Those with impaired fasting glucose only were much more likely to be 
reclassified as normal (adjusted RRR 8.41) or type 2 diabetes (adjusted RRR 17.7). Age and 
weeks between tests were inversely associated with reclassification as normal.  
7 | P a g e  
 
Multiple logistic regression (Table 4) showed that, after adjustment for baseline covariates, 
those initially classified as having type 2 diabetes according to both FPG and HbA1c were 
much less likely to be reclassified as normal or non-diabetic hyperglycaemia than those 
classified according to HbA1c alone (odds ratio 0.28). Smaller waist circumference and more 
weeks between tests were independently associated with reclassification.  
Multiple linear regression (Table 5) showed that, in participants with an initial diagnosis of non-
diabetic hyperglycaemia, initial FPG, BMI and weeks between tests were independently 
associated with increased HbA1c between initial and second tests, and initial HbA1c and body 
fat mass were associated with decreased HbA1c. In participants with an initial diagnosis of 
type 2 diabetes, initial FPG and total cholesterol were independently associated with increased 
HbA1c, and initial HbA1c and low density lipoprotein were independently associated with 
decreased HbA1c (Table 5). 
Discussion  
This study shows that, in a population-based screening study to diagnose non-diabetic 
hyperglycaemia for entry into a diabetes prevention trial, high proportions of those initially 
classified by HbA1c as having non-diabetic hyperglycaemia (28%) and type 2 diabetes (21%) 
had different classifications when retested a few weeks later. Because HbA1c and fasting 
plasma glucose are known to vary randomly within individuals over time, it was predictable 
that individuals found to have high glucose or HbA1c levels on initial testing would tend to 
have lower levels on retesting, because of regression to the mean. Regression to the mean 
occurs when measurements are repeated which include some random variation, due either to 
true variation in the parameter being measured, or to measurement error, or both [22,23]. 
Individuals with initial measurements that are higher or lower than the average would tend to 
have repeated measurements that are closer to the average, due to chance alone. As 
participants in the present study were selected because they had HbA1c measurements that 
were higher than the average, it was to be expected that their repeated measurements would 
be lower, on average, than before, and more so for those with the highest initial values. The 
negative associations between initial HbA1c and change in HbA1c (Table 5) confirm that such 
regression to the mean did occur. We also found that decreases in HbA1c, and the probability 
of discordant classifications, were greater with more time between tests (Tables 3-5), which 
could be due to secular trends in true glycaemic levels [23], for example if participants’ diet 
and activity changed after initial testing. .  
Because repeated testing was carried out only in participants with elevated HbA1c or FPG, 
and not in those with normal test results, this study does not therefore provide complete 
evidence about the test-retest reliability of glycaemic classification based on HbA1c. What it 
provides is evidence about how reliable this classification is among participants initially 
classified at abnormal in a screening study. Screening programmes typically follow an 
abnormal screening test with a second, confirmatory, test before delivering an intervention. 
They do not typically repeat tests in those initially classified as normal, which would add to the 
cost of screening and further complicate decisions about appropriate management  of 
participants with discordant classifications. The results of this study show that, to increase 
certainty that participants in screening truly have type 2 diabetes or non-diabetic 
hyperglycaemia that is not transient, it is desirable to repeat the test.  
This study adds to our previous report [13] by investigating the value of participant 
characteristics other than initial HbA1c results in predicting whether individuals had discordant 
non-diabetic hyperglycaemia and type 2 diabetes diagnoses on retesting. The study showed 
that initial diagnosis of prediabetes according to both HbA1c and FPG criteria made 
reclassification as normal less likely, and reclassification as type 2 diabetes more likely, than 
initial classification according to HbA1c alone. Initial diagnosis of type 2 diabetes according to 
both HbA1c and FPG criteria also made reclassification much less likely than initial 
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classification according to HbA1c alone. Although age and various anthropometric and 
biological measurements independently predicted discordant diagnoses and changes in 
HbA1c, these associations were inconsistent and so do not help to identify individuals who 
most need retesting. 
This approach is important in scoping capacity for national prevention programmes [5], and to 
normal clinical practice. It is estimated from the Health Survey for England that 10.7% of adults 
in England have non-diabetic hyperglycaemia [24] and national policy is that all such people 
should have diabetes prevention advice [5]. In the UK, this workload would fall largely on 
primary care and current workload pressures are such that some form of risk stratification and 
targeted intervention seems clinically essential. These data support modelling to develop a 
more focussed risk stratified approach. 
When interpreting HbA1c data for diagnosis and monitoring, it is vital to understand 
Uncertainty of Measurement (UoM), which includes Biological Variation and the Total 
Analytical Error. The Total Analytical Error comprises the analytical imprecision and bias of 
the method and can be assessed using Sigma-metrics. Sigma-metrics targets for HbA1c have 
been published [25]. The HbA1c method used in the NDPS conforms to this quality standard 
and is standardized to the international Reference Measurement Procedure [26] as 
recommended in the worldwide consensus statement [27]. The analytical imprecision for the 
HbA1c method used is <3% coefficient of variation [87]; within-individual biological variation 
is relatively small compared to the between-person variation in people without diabetes [29]. 
The analytical imprecision of the HbA1c assay in routine clinical use at the laboratory where 
the present study was carried out is as follows. Internal Quality Control (IQC) material is 
analysed at regular intervals throughout the day. The running mean and standard deviation 
(SD) are continuously updated and the between-day imprecision for one month (236 data 
points at each level) calculated. The low IQC target value  is 37 mmol/mol and the running 
mean was 36.8 mmol/mol; SD 0.7 mmol/mol; coefficient of variation (CV) 1.9%. The high IQC 
target value is 100 mmol/mol and the  running mean was 100.0 mmol/mol; SD 2.0 mmol/mol; 
CV 2.0%. Based on UoM, a change of >5 mmol/mol in HbA1c measurement reflects a true 
change in glycemic category and a difference of 42 to 48 mmol/mol (6.0% to 6.5%) in a repeat 
measurement may simply be accounted for by UoM. This UoM has to be recognised when 
categorizing participants, and reinforces the value of paired confirmatory data for glycemic 
categorization, particularly for participants with results close to a diagnostic threshold. Lifestyle 
and genetic variance to glycation and HbA1c variability (independent of glycemic profiles) are 
also reported to have an effect on the measured HbA1c [30] 
The study had several limitations. Only people at risk of diabetes were invited to be tested, 
only 9% of them consented to be tested, and only those with elevated HbA1c or FPG were 
retested, so the results are not generalizable to the whole East of England population. 
However the participants in this study represent people who would be most likely to participate 
in a diabetes prevention programme and to be identified as having non-diabetic 
hyperglycaemia or type 2 diabetes. As 96% of participants were white British from one region 
of England, generalisability would be affected if cultural, behavioural or genetic factors 
influence HbA1c variability over time.  To assess the repeatability of these diagnostic tests 
more generally it would have been better to have had  retest data on all 10,000 participants in 
screening, but these data were not available. Alternative analyses using the American Diabetic 
Association  definition of prediabetes [17], may have produced different results but would not 
be directly relevant to the NHS and its Diabetes Prevention Programme [19].  
Population-based diabetes prevention and screening programmes need to address this 
problem of reproducibility of diagnostic testing.  Confirmation of diagnosis by repeated testing 
is necessary and clear policies are needed for management of individuals with discordant test 
results.  
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of type 2 
diabetes 
P* Participants with 
impaired fasting 
glucose and without 
non-diabetic 
hyperglycaemia or 
type 2 diabetes on 
initial test 
 No. (%) No.  (%) No.  (%)  No.  (%) No.  (%)  No. (%) 
Total participants 2208 (100) 416  (100) 1047  (100)  83 (100) 311 (100)  351 (100) 
Demographic characteristics and 
medical history 
        
Female  928 (42.0) 187 (45.0)  458 (43.7) 0.675 31 (37.4) 129 (41.5) 0.496 118 (33.6) 
Ethnicity    0.180   0.477  
 White British 2070 (93.4) 392 (95.2) 993 (96.0)  74 (89.2) 284 (91.3)  326 (92.9 
 Any other white background 39 (1.8) 8 (1.9) 24 (2.3)  6 (7.2) 11 (3.5)  11 (3.1) 
 Other ethnic group 69 (3.1) 12 (2.9) 17 (1.6)  2 (2.4) 11 (3.5)  7 (2.0) 
 Not recorded 30 (1.4) 0 (0.0) 0 (0.0)  1 (1.2) 5 (1.6)  7 (2.0) 
History of gestational diabetes  61   (5.5%) 10 (2.4) 29 (2.8) 0.695 3 (3.6) 9 (2.9) 0.734 9 (2.6) 
Family history type 2 diabetes  934 (42.3%) 168 (40.4) 444 (42.4) 0.479 32 (38.6) 140 (45.0) 0.292 145 (41.3) 
Family history cardiovascular disease  357 (16.2%) 59 (14.2) 188 (18.0) 0.082 11 (13.3) 53 (17.0) 0.406 46 (13.1) 
 Mean (SD) Mean  (SD) Mean  (SD)  Mean (SD) Mean  (SD)   
Age (years) 65.0 (9.5) 64.2 (9.9) 66.5 (9.1) <0.001 66.2 (9.2) 64.3 (10.1) 0.129 64.2 (9.5) 
Weeks between first and second test 11.9 (15.1) 16.3 (17.4) 13.9 (16.5) 0.012 8.6 (10.9) 5.8 (5.6) 0.002 5.2 (5.1) 
Anthropometric measurements         
Body mass index 31 (5.7) 31.8 (5.9)) 31.1 (5.4) 0.032 31.0 (6.3) 33.3 (6.8) 0.003 30.8 (5.6) 
Waist circumference (cm) 107 (14) 106 (14) 106 (14) 0.152 106.0 (13.3) 111.7 (13.8) 0.001 105 (14.1) 
Body fat percentage 36 (12) 36.8 (9.1) 36.4 (14.0) 0.534 35.5 (8.7) 38.5 (8.7) 0.008 34.4 (9.3) 
Visceral fat percentage 15 (5) 15.3 (5.2) 15.2 (4.7) 0.757 15.6 (5.1) 16.7 (5.3) 0.099 15.1 (4.4) 
Body fat mass (Kg) 33 (12) 34 (12) 32 (12) 0.023 32.2 (11.9) 37.1 (12.9) 0.002 31.6 (12.5) 
Systolic blood pressure (mm Hg) 142 (17) 142 (17) 141 (17) 0.485 140 (18) 143 (18) 0.416 142 (17) 
Diastolic blood pressure (mm Hg) 82 (10) 82 (10) 81 (10) 0.050 82 (10) 83 (11) 0.305 82 (10) 
Biochemical measurements         
Initial HbA1c (mmol/mol) 44.7 (6.0) 43.5 (1.6) 44.0 (1.5) <0.001 48.9 (1.5) 54.7 (8.9) <0.001 39.1 (2.3) 
Initial HbA1c (%) 6.2 (0.5) 6.1 (0.1) 6.2 (0.1) <0.001 6.6 (0.8) 7.2 (0.9) <0.001 5.7 (4.7) 
Initial fasting plasma glucose (mmol/L) 6.1 (1) 5.7 (0.7)  5.9 (0.6) 0.002 6.2 (1.3) 7.3 (1.8) <0.001 6.3 (0.3) 
Total cholesterol (mmol/L) 5.1 (1.2) 5.2 (1.2) 5.1 (5.1) 0.422 5.2 (0.3) 5.2 (1.3) 0.777 5.1 (1.1) 
High density lipoprotein (mmol/L) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 0.983 1.3 (0.9) 1.2 (0.3) 0.277 1.3 (0.3 
Low density lipoprotein (mmol/L) 3.1 (1.0) 3.2 (1.0) 3.1 (1.0) 0.661 3.1 (0.7) 3.1 (1.1) 0.966 3.1 (0.9) 
Triglycerides (mmol/L) 1.6 (0.9) 1.7 (0.8) 1.6 (0.7) 0.045 1.7 (0.7) 1.9 (1.1) 0.127 1.6 (1.1) 
 
Legend: * Participants with discordant and concordant classifications were compared with chi square or t test 
12 | P a g e  
 
Table 2. Comparison between initial classification of non-diabetic hyperglycaemia and/or impaired 
fasting glucose *, or type 2 diabetes, based on initial HbA1c and/or fasting plasma glucose, and second 
classification, based on second HbA1c 
 
















and/or impaired fasting 
glucose * based on: 
No. % No. % No. % No. % 
 HbA1c only 177 26.6 455 68.3 34 5.1 666 100.0 
 HbA1c and fasting 
plasma glucose 
135 17.0 592 74.3 70 8.8 797 100.0 
 Fasting plasma glucose 
only 
250 46.6 129 24.0 158 29.4 534 100.0 
Total 562 28.1 1176 58.8 262 13.1 2000 100.0 
 Chi2=407.2 df=4, P<0.001 
         
Type 2 diabetes, based on:         
 HbA1c only 1 0.4 68 27.8 175 71.7 244 100.0 
 HbA1c and fasting 
plasma glucose 
0 0.0 14 9.3 136 90.7 150 100.0 
 Fasting plasma glucose 
only 
8 13.1 46 75.4 7 11.5 61 100.0 
Total 9 2.0 128 28.1 318 70.0 455 100.0 
 Chi2=150.7 df=4, P<0.001 
* Impaired fasting glucose if fasting plasma glucose >5.6 and <7.0 mmol/L.  
 
  
13 | P a g e  
 
Table 3. Prediction of discordant classification (normality or type2 diabetes versus non-diabetic 
hyperglycaemia), based on second HbA1c test, in participants with classification of non-diabetic 
hyperglycaemia and/or impaired fasting glucose * based on initial HbA1c and/or fasting plasma glucose: 
multinomial logistic regression model 
Outcome: Normal vs. non-diabetic hyperglycaemia 




Non-diabetic hyperglycaemia and/or impaired 
fasting glucose * based on: 
   
 HbA1c only (reference) 1.00   
 HbA1c and fasting plasma glucose 0.91 (0.63 - 1.31) 0.622 
 Fasting plasma glucose only 8.41 (5.8 - 12.2) <0.001 
Age (years) 0.98 (0.96 - 0.99) 0.002 
Body mass index 1.00 (0.98 - 1.02) 0.966 
Triglycerides (mmol/L) 0.99 (0.84 - 1.17) 0.911 
Diastolic blood pressure (mm Hg) 1.01 (0.94 - 0.98) 0.234 
Weeks between first and second test 0.96 (0.11 - 4.36) <0.001 
    
Outcome: Type 2 diabetes vs. non-diabetic hyperglycaemia 




Non-diabetic hyperglycaemia and/or impaired 
fasting glucose  based on: 
   
 HbA1c only (reference)  1.00  
 
 HbA1c and fasting plasma glucose 1.62 (0.94 - 2.80) 0.081 
 Fasting plasma glucose only 17.7 (10.3 - 30.5) <0.001 
Age (years) 0.99 (0.97 - 1.01) 0.248 
Body mass index 1.05 (1.02 - 1.08) 0.001 
Triglycerides (mmol/L) 1.15 (0.97 - 1.37) 0.116 
Diastolic blood pressure (mm Hg) 1.01 (0.99 - 1.03) 0.281 
Weeks between first and second test 1.00 (0.99 - 1.02) 0.687 
* Non-diabetic hyperglycaemia if HbA1c 42-47 mmol/mol (6.0-6.4%), and/or impaired fasting glucose if 
fasting plasma glucose 5.6-7.0 mmol/L.  
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Table 4. Prediction of discordant classification (normality or non-diabetic hyperglycaemia versus type 2 
diabetes) based on second HbA1c test, in participants with classification of type 2 diabetes based on 
initial HbA1c and/or fasting plasma glucose: logistic regression model 






Type 2 diabetes, based on:    
 HbA1c only (reference) 1.00   
 HbA1c and fasting plasma glucose 0.28 (0.15 - 0.54) <0.001 
 Fasting plasma glucose only 20.5 (8.8 - 48.1) <0.001 
Body mass index 1.00 (0.94 - 1.08) 0.910 
Waist circumference (cm) 0.96 (0.92 - 1.00) 0.029 
Visceral fat percentage 1.07 (0.99 - 1.15) 0.084 
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Table 5. Association between baseline measurements and change in HbA1c value (mmol/mol) in participants with initial diagnosis of non-diabetic 
hyperglycaemia or type 2 diabetes: linear regression models 
  
Participants with initial diagnosis of non-
diabetic hyperglycaemia 
 
Participants with initial diagnosis of 
type 2 diabetes 
Explanatory variable Coefficient (95% CI) 
 
P Coefficient (95% CI) 
 
P 
Initial HbA1c (mmol/mol) -0.16 (-0.25, -0.08) <0.001 -0.17 (-0.25, -0.09) <0.001 
Initial fasting plasma glucose (mmol/L) 0.49 (0.27, 0.72) <0.001 0.67 (0.25, 1.09) 0.002 
Body mass index 0.05 (0.00, 0.11) 0.038 0.05 (-0.08, 0.17) 0.493 
Body fat mass (Kg) -0.03 (-0.05, 0.00) 0.023 -0.02 (-0.08, 0.04) 0.588 
Total cholesterol (mmol/L) 0.32 (-0.12, 0.76) 0.158 1.10 (0.20, 2.00) 0.016 
High density lipoprotein (mmol/L) -0.46 (-0.97, 0.05) 0.077 -0.53 (-1.86, 0.80) 0.434 
Low density lipoprotein (mmol/L) -0.19 (-0.68, 0.30) 0.451 -1.15 (-2.18, -0.12) 0.028 
Weeks between first and second test 0.04 (0.03, 0.05) <0.001 -0.05 (-0.11, 0.02) 0.139 
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